Insiders' Blog
Sponsored by: Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!
Icahn's Icahn Capital Boosts Stake in Biogen (BIIB) to Nearly 10M Shares
More News related to BIIB
- Biogen Idec Announces Certified Stockholder Vote Results, Confirming Election of All Four of the Board's Director Nominees
- Biogen Idec to Report Second Quarter 2008 Financial Results on July 22, 2008
- Biogen Idec Stockholders Elect Company's Board Nominees
- Carl Icahn Loses Proxy Battle At Biogen Idec (BIIB)-WSJ
- Deutsche Bank Starts Biogen-IDEC (BIIB) at Hold
More News related to Insiders' Blog
- IMAX Corporation (IMAX) Spikes Today As Its Theaters Are Sold Out Across The Country
- Freeport (FCX) Spikes on Takeover Chatter; Vale (RIO) Denies Rumors
- Piper Jaffray Downgrades Infinity Property and Casualty (IPCC) To Neutral
- VMware (VMW) Re-Prices Stock Options For Employees To A Price More Reflective Of VMware's Current Price
- UBS Raises Price Targets on Potash (POT) and Agrium (AGU)
Carl Icahn's Icahn Capital latest 13F shows he raised his stake in Biogen Idec (Nasdaq: BIIB).
Icahn's filing showed he boosted his stake from 8,256,723 shares to 9,948,723 shares.
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally.
Related Categories
Insider TradesInsiders' Blog
Stocks Mentioned
+1.65Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
